Anbio Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	7.77	11.76	9.69	7.1	4.18
Short-Term Investments	4.13	-	-	1.57	-
Cash & Short-Term Investments	11.9	11.76	9.69	8.67	4.18
Cash Growth	1.19%	21.40%	11.75%	107.33%	-
Accounts Receivable	3.66	1.06	1.88	-	0.72
Inventory	-	-	-	0.35	-
Other Current Assets	14.69	5.71	4.18	4.92	0.02
Total Current Assets	30.24	18.53	15.75	13.94	4.92
Net Property, Plant & Equipment	-	-	0.01	-	-
Other Long-Term Assets	-	0.39	0.06	0	-
Total Assets	30.24	18.92	15.81	13.96	4.92
Accounts Payable	-	1.63	0.83	1.41	1.89
Unearned Revenue	-	-	-	-	0.49
Other Current Liabilities	0.09	0.1	0.17	0	-
Total Current Liabilities	0.09	1.73	0.99	1.41	2.38
Total Liabilities	0.09	1.73	0.99	1.41	2.38
Common Stock	0.01	0.01	0.01	-	-
Additional Paid-in Capital	6.56	0	0	-	-
Retained Earnings	23.58	17.17	14.8	12.55	2.54
Shareholders' Equity	30.16	17.19	14.82	12.55	2.54
Total Liabilities & Equity	30.24	18.92	15.81	13.96	4.92
Net Cash (Debt)	11.9	11.76	9.69	8.67	4.18
Net Cash Growth	1.19%	21.40%	11.75%	107.33%	-
Net Cash Per Share	0.27	0.28	0.45	86690.60	41813.30
Book Value	30.16	17.19	14.82	12.55	2.54
Book Value Per Share	0.69	0.41	0.69	125470.00	25358.10
Tangible Book Value	30.16	17.19	14.82	12.55	2.54
Tangible Book Value Per Share	0.69	0.41	0.69	125470.00	25358.10

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q